CClinicalTrials.gg
CompletedNCT05041621Updated Nov 9, 2023

A Learning Algorithm for MDI Individuals With Type 1 Diabetes to Adjust Recommendations for High Fat Meals and Exercise Management

An interventional study of Sensor augmented MDI therapy plus mobile application in Type 1 Diabetes, sponsored by McGill University. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by McGill University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

McGill artificial pancreas lab has developed a learning algorithm using a reinforcement learning approach to adjust basal and bolus recommendations for high-fat meals and exercise management for individuals with type 1 diabetes on multiple daily injections (MDI) therapy. The reinforcement learning algorithm is integrated with a mobile application that gathers insulin, meal information (carbs (if applicable) and high-fat content), mealtime glucose value, glucose trend at mealtime, and type and timing of postprandial exercise.

Read the detailed description

The objective of this study is to assess the feasibility of a reinforcement learning algorithm to adjust basal and bolus recommendations for high-fat meals and postprandial exercise management. The investigators hypothesize that the reinforcement learning algorithm will be safe, and participants will get the benefit of improved glucose outcomes and improved patient satisfaction from the start to the end of study.

Participants (aged ≥18) will undergo multiple daily injections (MDI) therapy for 4 months using a freestyle Libre glucose sensor (Abbott Diabetes Care) and a mobile data collection application integrated with the reinforcement learning algorithm.

02

Conditions studied

03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 15 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

McGill University is the lead sponsor of 244 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Signed and dated informed consent form
  2. Females and males ≥ 18 years old
  3. Diagnosis of type 1 diabetes of ≥ 12 months based on the clinical investigator's judgement
  4. Undergoing MDI therapy
  5. A self-reported diet that consists of at least 3 high-fat meals per week or participation in exercise for at least 30 minutes, two times per week

Exclusion criteria

Exclusion Criteria:

  1. Current use of any non-insulin antihyperglycemic medication (SGLT2 inhibitors, GLP 1 receptor agonists, metformin...)
  2. Current use of glucocorticoid medication, except inhaled and/or at low stable doses
  3. Pregnancy
  4. Use of isophane insulin (NPH) or intermediate-acting insulin
  5. Significant clinical nephropathy, neuropathy, retinopathy as per the clinical investigator's judgement
  6. Acute macrovascular event (ex: acute coronary syndrome or cardiac surgery) within 6 months of admission
  7. Severe diabetes ketoacidosis and/or hypoglycemia within one month of admission
  8. Other severe medical illness that the clinical investigator considers may interfere with participation in or completion of the study
  9. An inability or unwillingness to comply with study procedures as per the clinical investigator's judgement
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Sensor augmented MDI therapy plus mobile application with reinforcement learning algorithm

    Participants with type 1 diabetes will undergo sensor-augmented MDI therapy for 4 months using a freestyle libre glucose sensor (Abbott Diabetes Care) and a mobile application integrated with the reinforcement learning algorithm.

    Device: Sensor augmented MDI therapy plus mobile application

Interventions

  • DeviceSensor augmented MDI therapy plus mobile application

    Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions. All participants will be asked to complete the: (i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention. (ii) mHealth usability questionnaire (MAUQ) at post-intervention.

06

What researchers measure

Primary outcomes

  1. Comparison of 5 hours postprandial incremental area under the curve of glucose (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  2. Comparison of 5 hours postprandial percentage of time below 3.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

Secondary outcomes

  1. Comparison of 5 hours postprandial percentage of time between 3.9 and 10 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  2. Comparison of 5 hours postprandial percentage of time between 3.9 and 7.8 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  3. Comparison of 5 hours postprandial percentage of time below 3.3 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  4. Comparison of 5 hours postprandial percentage of time below 2.8 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  5. Comparison of 5 hours postprandial percentage of time above 7.8 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  6. Comparison of 5 hours postprandial percentage of time above 10 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  7. Comparison of 5 hours postprandial percentage of time above 13.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  8. Comparison of 5 hours postprandial percentage of time above 16.7 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  9. Comparison of 5 hours postprandial mean glucose level (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  10. Comparison of 5 hours postprandial standard deviation of glucose levels (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  11. Comparison of 5 hours postprandial coefficient of variance of glucose levels (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last month of intervention, approximately 4 months

  12. Comparison of 24 hours incremental area under the curve of glucose levels (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  13. Comparison of 24 hours percentage of time below 3.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  14. Comparison of 24 hours percentage between 3.9 and 10 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  15. Comparison of 24 hours percentage between 3.9 and 7.8 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  16. Comparison of 24 hours percentage of time below 3.3 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  17. Comparison of 24 hours percentage of time below 2.8 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  18. Comparison of 24 hours percentage of time above 10 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  19. Comparison of 24 hours percentage of time above 13.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  20. Comparison of 24 hours percentage of time above 16.7 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  21. Comparison of 24 hours mean glucose level (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  22. Comparison of 24 hours standard deviation of glucose levels (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  23. Comparison of 24 hours coefficient of variance of glucose levels (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations

    Time frame: First and last week of intervention, approximately 4 months

  24. Quality of life measure by Hypoglycemic Fear Survey - II: score is the average of 18 items and each item scores ranges 1 to 5 to select (average of higher scores equates to more distress)

    Time frame: Pre-intervention, mid-way intervention, and post-intervention, approximately 4 months

  25. Quality of life measure by Hypoglycemic Fear Survey - II: score is the average of 9 items and each item scores ranges 0 to 6 (average of higher scores equates to more satisfied with the treatment)

    Time frame: Pre-intervention, mid-way intervention, and post-intervention, approximately 4 months

  26. Mobile app usability questionnaire: score is the average of 16 items and each item scores ranges 0-6 (average of higher scores means higher usability)

    Time frame: Post-intervention, approximately 4 months

07

Study locations

1 site
  • Clinique Médicale Hygea
    Montreal, Quebec H4A 3T2, Canada
08

References and documents

Individual participant data

Plan to share: Yes — The raw data (insulin delivery, glucose levels, individual participant data) could be shared by the corresponding author, ahmad.haidar@mcgill.ca, upon reasonable request for academic purposes, subject to Material Transfer Agreement and approval of McGill University Health Center's Research Ethics Board. All data shared will be deidentified. Study protocol is available with publication.

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05041621
Lead sponsor
McGill University
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Jul 7, 2021
Primary completion
Feb 21, 2023
Completion
Feb 21, 2023
Last update
Nov 9, 2023

Study contacts

Ahmad Haidar, PhD
study chair · McGill University Health Centre/Research Institute of the McGill University Health Centre
Michael Tsoukas, MD
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion